ArticleParasite immunology2018
Immunotherapy of alveolar echinococcosis via PD-1/PD-L1 immune checkpoint blockade in mice.
Article in Parasite immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 57 citations in OpenAlex.
- Human leukocyte extract enhances albendazole efficacy against Echinococcus multilocularis in mice by reducing parasitic microRNAs, myeloid and lymphoid immunosuppressive cells.PLoS neglected tropical diseases · 2026Article
- Polarization of Hepatic Macrophages in Alveolar Echinococcosis and Its Role in Remodeling the Immune Microenvironment.Tropical medicine and infectious disease · 2026Review
- LAG3 constrains anti-parasitic response by effector CD4Parasites & vectors · 2026Article
- Serum sPD-1 as a marker of T cell exhaustion in ART-naïve, ART-experienced, and intestinal parasite co-infected HIV-positive adults at the university of Gondar comprehensive specialized hospital, Northwest Ethiopia, 2024.BMC infectious diseases · 2025Article
- Spatiotemporal Transcriptomic Profiling Reveals the Dynamic Immunological Landscape of Alveolar Echinococcosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Current status of drug therapy for alveolar echinococcosis.World journal of hepatology · 2024Review
- High PD-1 and CTLA-4 expression correlates with host immune suppression in patients and a mouse model infected with Echinococcus multilocularis.Parasites & vectors · 2024Article
- Targeting myeloid-derived suppressor cells promotes antiparasitic T-cell immunity and enhances the efficacy of PD-1 blockade (15 words).Nature communications · 2024Article
- The expression of CTLA-4 in hepatic alveolar echinococcosis patients and blocking CTLA-4 to reverse T cell exhaustion inFrontiers in immunology · 2024Article
- Phenotype and function of MAIT cells in patients with alveolar echinococcosis.Frontiers in immunology · 2024Article
- Upregulation of LAG3 modulates the immune imbalance of CD4+ T-cell subsets and exacerbates disease progression in patients with alveolar echinococcosis and a mouse model.PLoS pathogens · 2023Article
- Basic Operative Tactics for Pulmonary Echinococcosis in the Era of Endostaplers and Energy Devices.Medicina (Kaunas, Lithuania) · 2023Review
- NIR-II fluorescence microscopic bioimaging for intrahepatic angiography and the early detection ofFrontiers in bioengineering and biotechnology · 2023Article
- Drug Repurposing to Enhance Antitumor Response to PD-1/PD-L1 Immune Checkpoint Inhibitors.Cancers · 2022Review
- Salvage Therapy for Alveolar Echinococcosis-A Case Series.Pathogens (Basel, Switzerland) · 2022Article
- Evaluation of Allicin Against Alveolar Echinococcosis In Vitro and in a Mouse Model.Acta parasitologica · 2022Article
- Advances in the pharmacological treatment of hepatic alveolar echinococcosis: From laboratory to clinic.Frontiers in microbiology · 2022Review
- Albendazole reduces hepatic inflammation and endoplasmic reticulum-stress in a mouse model of chronic Echinococcus multilocularis infection.PLoS neglected tropical diseases · 2022Article
- Maca against Echinococcosis?-A Reverse Approach from Patient to In Vitro Testing.Pathogens (Basel, Switzerland) · 2021Article
- Revisiting the Mechanisms of Immune Evasion Employed by Human Parasites.Frontiers in cellular and infection microbiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
The growth potential of the tumour-like Echinococcus multilocularis metacestode (causing alveolar echinococcosis, AE) is directly dependent upon the nature/function of the periparasitic adaptive host immune-mediated processes. PD-1/PD-L1 pathway (programmed cell death 1), which inhibits lymphocytic proliferation in tumour development, is over-expressed at the chronic stage of AE. We tested the impact of a PD-1/PD-L1 pathway blockade on the outcome of both chronic AE (intraperitoneal metacestode inoculation, secondary AE and SAE) and acute AE (peroral egg infection, primary AE and PAE). To assess the parasite proliferation potential, we measured parasite mass weight for SAE and liver lesion number for PAE. In both models, the parasite load was significantly decreased in response to anti-PD-L1 antibody treatment. In SAE, anti-PDL1 administration was associated with increased Th1 response parameters and decreased Treg responses, while in PAE anti-PDL1 administration was associated with fewer lesions in the liver and decreased Treg/Th2 responses. Our findings highly suggested that a PD-1/PD-L1 pathway blockade triggered the host immune responses in favour of an immune-mediated control of E. multilocularis proliferation. Based on this, future studies that combine PD-1/PD-L1 blockade with a parasitostatic albendazole medication may yield in a putatively curative therapeutic approach to control alveolar echinococcosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.